For research and educational purposes only. Not medical advice.
Ziconotide Reference
Educational, not medical advice reference for Ziconotide: Hormonal; regulatory status, evidence posture, source review, and schedule notes. Also known as Pri…
Reference summary
Ziconotide is a label-verified synthetic omega-conotoxin (Cav2.2 N-type calcium channel blocker) with FDA Phase 3 evidence in severe chronic pain refractory to other intrathecal therapy. pepSmart surfaces label-reference content only.
- Categories
- Hormonal
- Aliases
- Prialt, SNX-111, Synthetic omega-conotoxin MVIIA, Cav2.2 N-type calcium channel blocker
- Evidence posture
- human - Boxed warning per label: severe psychiatric symptoms and neurological impairment may occur during treatment. Contraindicated in patients with pre-existing psychosis. Intrathecal infusion only via implanted programmable pump - not for IV, IM, SC, or oral administration. No consumer self-administration pathway exists.
- Regulatory status
- FDA-approved prescription medication (Prialt). Initial US approval 2004. Indicated for management of severe chronic pain in adult patients for whom intrathecal therapy is warranted and who are unresponsive to or intolerant of other treatments including systemic analgesics, adjunctive therapies, or intrathecal morphine. Intrathecal infusion only via implantable programmable microinfusion device. Prescription-only and clinician-managed.
- Content review status
- label verified